Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells

References

• Pleyer L, Egle A, Hartmann TN, . Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009;6:405–418.
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Ann Rev Immunol 2003;21:841–894.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Huynh L, Toy TL, . ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893–901.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh AA, Widhopf G, . Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639–1647.
   PubMed Web of Science ®Google Scholar
• Damle RN, Ghiotto F, Valetto A, . B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002;99:4087–4093.
   PubMed Web of Science ®Google Scholar
• Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2002;6:283–294.
   Web of Science ®Google Scholar
• Gobessi S, Laurenti L, Longo PG, . Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2009;23:686–693.
   PubMed Web of Science ®Google Scholar
• Contri A, Brunati AM, Trentin L, . Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005;115:369–378.
   PubMed Web of Science ®Google Scholar
• Ringshausen I, Oelsner M, Weick K, . Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. Leukemia 2006;20:514–520.
   PubMed Web of Science ®Google Scholar
• Pekarsky Y, Palamarchuk A, Maximov V, . Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci USA 2008;105:19643–19648.
   PubMed Web of Science ®Google Scholar
• Yan XJ, Albesiano E, Zanesi N, . B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006; 103:11713–11718.
   PubMed Web of Science ®Google Scholar
• Yan XJ, Albesiano E, Zanesi N, . Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of non hematopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Res 2006;66:915–920.
   PubMed Web of Science ®Google Scholar
• Holler C, Piñón JD, Denk U, . PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood 2009;113:2791–2794.
   PubMed Web of Science ®Google Scholar
• Ma S, Rosen ST. Enzastaurin. Curr Opin Oncol 2007;19:590–595.
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR, . The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65:7462–7469.
   PubMed Web of Science ®Google Scholar
• Herbst R, Thornton DE, Kies MS, . Phase I study of LY317615, a protein kinase Cβ inhibitor. Proc Am Soc Clin Oncol 2002;>21(Suppl.): Abstract 326.
   Google Scholar
• Green LJ, Marder P, Ray C, . Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clin Cancer Res 2006;12:3408–3415.
   PubMed Web of Science ®Google Scholar
• Raab M, Breitkreutz I, Tonon G, . Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood 2009;113:1513–1521.
   PubMed Web of Science ®Google Scholar
• zum Büschenfelde CM, Wagner M, Lutzny G, . Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia 2010;24:141–152.
   PubMed Web of Science ®Google Scholar
• Dumstorf CA, Konicek BW, McNulty AM, . Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis. Mol Cancer Ther 2010;9:3158–3163.
   PubMedGoogle Scholar
• Liu Q, Zhao X, Frissora F, . FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008;111:275–284.
   PubMed Web of Science ®Google Scholar
• Moon EY, Lerner A. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. Blood 2003;101:4122–4130.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Suzuki Y, Kihira H, . Expressions of four major protein Ser/Thr phosphatases in human primary leukemic cells. Leukemia 1999;13:595–600.
   PubMed Web of Science ®Google Scholar
• Janssens V, Longin S, Goris J. PP-2A holoenzyme assembly: in cauda venenum. Trends Biochem Sci 2008;33:113–121.
   PubMed Web of Science ®Google Scholar
• Thomas A, Pepper C, Hoy T, . Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma 2004;45:997–1008.
   PubMed Web of Science ®Google Scholar
• Moreau AS, Jia X, Ngo HT, . Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström macroglobulinemia. Blood 2007;109:4964–4972.
   PubMed Web of Science ®Google Scholar
• Deng X, Gao F, May WS. Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood 2009;113:422–428.
   PubMed Web of Science ®Google Scholar
• Kuo WL, Liu J, Mauceri H, . Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther 2010;9:2814–2824.
   PubMed Web of Science ®Google Scholar
• Lin SS, Bassik MC, Suh H, . PP-2A regulates Bcl-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem 2006;281:23003–23012.
   PubMed Web of Science ®Google Scholar
• Baudot AD, Jeandel PY, Mouska X, . The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene 2009;28:3261–3273.
   PubMed Web of Science ®Google Scholar